Pharmacokinetics and pharmacodynamics of multiple sublingual buprenorphine tablets in dose-escalation trials.
about
Memory function in opioid-dependent patients treated with methadone or buprenorphine along with benzodiazepine: longitudinal change in comparison to healthy individualsEndogenous opiates and behavior: 2006Preliminary buprenorphine sublingual tablet pharmacokinetic data in plasma, oral fluid, and sweat during treatment of opioid-dependent pregnant womenBuprenorphine for opioid dependenceSublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone.Inhibition of CYP2D6-mediated tramadol O-demethylation in methadone but not buprenorphine maintenance patients.Buprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives.Can the chronic administration of the combination of buprenorphine and naloxone block dopaminergic activity causing anti-reward and relapse potential?The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers.Withdrawal from Buprenorphine/Naloxone and Maintenance with a Natural Dopaminergic Agonist: A Cautionary Note.Rifampicin decreases exposure to sublingual buprenorphine in healthy subjects.Buprenorphine for cancer pain: is it ready for prime time?Effect of Buprenorphine Weekly Depot (CAM2038) and Hydromorphone Blockade in Individuals With Opioid Use Disorder: A Randomized Clinical Trial.A physiologically based pharmacokinetic modelling approach to predict buprenorphine pharmacokinetics following intravenous and sublingual administration.An evidence-based recommendation to increase the dosing frequency of buprenorphine during pregnancy.Drug interactions between buprenorphine, methadone and hepatitis C therapeutics.Randomised Comparison of a Novel Buprenorphine Oral Lyophilisate versus Existing Buprenorphine Sublingual Tablets in Opioid-Dependent Patients: A First-in-Patient Phase II Randomised Open Label Safety Study.Voriconazole more likely than posaconazole increases plasma exposure to sublingual buprenorphine causing a risk of a clinically important interaction.
P2860
Q21203511-ED4A31F2-7B8E-420C-81ED-A2C82A56C96AQ28752585-337FDB34-B730-4279-8F25-A5E1A8402130Q34000757-0F654F39-5603-4D80-BAB5-E9218307A4B0Q34119459-793469C4-BA6A-4C5E-A4A9-2E631A07A519Q36170053-3E5012FF-38A2-4951-9F88-07E86561C88BQ36390262-E96929E7-F043-4C73-B223-FA0482EE6052Q36394429-8805277D-7FD5-4A14-8478-8EEE589111ACQ36928874-DBE7168E-4051-41F6-A6B8-AE0DD06D55F5Q37180966-4E9792FA-6772-4FFD-BC82-105FCE1D33B9Q37329865-DABF0A49-3B1B-45AD-AC85-2E6CABAF0669Q37579953-5977BA26-9E25-4433-93A6-CBF12B0BBB2FQ38243938-864C28F3-C132-443F-B429-1C37CC59A127Q38374886-C40A49E4-9919-433A-A237-C9B402190C3BQ38661092-C9750B59-9EEE-4328-B834-84EB355DEDB6Q38697804-8717C81D-E57F-425D-8075-ED5293227B32Q38824198-2F7B0DCB-63B4-4D2D-8E11-EA64416110AEQ44343800-3370CA87-B0EF-4964-8948-2E1C94C2D0EFQ51579656-C6863587-6BC6-4661-B021-64B1948C6A39
P2860
Pharmacokinetics and pharmacodynamics of multiple sublingual buprenorphine tablets in dose-escalation trials.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Pharmacokinetics and pharmacod ...... ets in dose-escalation trials.
@en
Pharmacokinetics and pharmacod ...... ets in dose-escalation trials.
@nl
type
label
Pharmacokinetics and pharmacod ...... ets in dose-escalation trials.
@en
Pharmacokinetics and pharmacod ...... ets in dose-escalation trials.
@nl
prefLabel
Pharmacokinetics and pharmacod ...... ets in dose-escalation trials.
@en
Pharmacokinetics and pharmacod ...... ets in dose-escalation trials.
@nl
P2093
P2860
P50
P356
P1476
Pharmacokinetics and pharmacod ...... ets in dose-escalation trials.
@en
P2093
C Nora Chiang
David J Greenblatt
Eugene Somoza
John Rotrosen
Robert J Hitzemann
P2860
P304
P356
10.1177/0091270005284192
P577
2006-02-01T00:00:00Z